A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy
Study sponsor: Xenon Pharmaceuticals Inc. · XENE
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-09-02Actual
Enrollment · participants325Actual
Source updated2026-11-05Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.